Johnson & Johnson $JNJ Stock Sold by Crossmark Global Holdings Inc.

Key Points

• Crossmark Global Holdings cut its Johnson & Johnson position by 17.2% in the third quarter, selling 5,977 shares and retaining 28,815 shares valued at $7.63 million. Institutional investors collectively own 69.55% of J&J.
• J&J beat quarterly expectations with $2.59 in adjusted EPS and $25.40 billion in revenue, while sales rose 5.9% year over year. The company reaffirmed 2026 EPS guidance of $11.05–$11.15 and declared a quarterly dividend of $1.34 per share, yielding about 2.0% annually.
• The stock opened at $264.13, near its $265.64 50-day average, with analysts maintaining a “Moderate Buy” consensus and an average price target of $275.92. However, the premium valuation, MedTech execution concerns and recent insider selling remain potential headwinds.

Crossmark Global Holdings Inc. lowered its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 17.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 28,815 shares of the company's stock after selling 5,977 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Johnson & Johnson were worth $7,628,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Silver Coast Investments LLC boosted its holdings in Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock valued at $271,000 after purchasing an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV increased its stake in Johnson & Johnson by 0.6% in the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after purchasing an additional 39 shares during the last quarter. Triumph Capital Management raised its holdings in Johnson & Johnson by 1.6% during the second quarter. Triumph Capital Management now owns 2,531 shares of the company's stock worth $643,000 after purchasing an additional 39 shares in the last quarter. Kwmg LLC raised its holdings in Johnson & Johnson by 1.7% during the third quarter. Kwmg LLC now owns 2,383 shares of the company's stock worth $631,000 after purchasing an additional 39 shares in the last quarter. Finally, Denali Advisors LLC lifted its position in shares of Johnson & Johnson by 1.2% during the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock worth $839,000 after buying an additional 40 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Down 1.3%

NYSE:JNJ opened at $264.13 on Friday. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.02. The stock has a fifty day moving average price of $265.64 and a two-hundred day moving average price of $250.21. The stock has a market capitalization of $635.85 billion, a price-to-earnings ratio of 40.02, a PEG ratio of 2.65 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business's revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 81.21%.

Insiders Place Their Bets

In related news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 64,515 shares of company stock valued at $17,271,766. Company insiders own 0.16% of the company's stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J's oral psoriasis pill
• Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data
• Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers
• Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment
• Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed
• Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns

Analyst Ratings Changes

Several research analysts have recently issued reports on JNJ shares. Citigroup upped their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a "buy" rating in a report on Monday, October 5th. Argus set a $300.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Johnson Rice cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Wednesday. Finally, Sanford C. Bernstein set a $270.00 price objective on shares of Johnson & Johnson in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $275.92.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.